Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
EU Regulator Backs First Oral IL-23 Receptor Drug for Plaque Psoriasis
00

EU Regulator Backs First Oral IL-23 Receptor Drug for Plaque Psoriasis

Jul 24, 2026

On July 24, 2026, the European Medicines Agency recommended granting marketing authorisation for Icotyde (icotrokinra) to treat moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older. As the first oral medicine targeting the interleukin-23 receptor, Icotyde offers a convenient alternative to existing injectable therapies. Phase 3 trials involving 2,500 patients demonstrated significant efficacy, with up to 71% achieving clear or almost clear skin, alongside a favourable safety profile.

EMA Icotyde marketing authorisation recommendation

  • ▪Icotyde is recommended for the treatment of moderate-to-severe plaque psoriasis in adults and adolescents from 12 years of age weighing at least 40 kg.
  • ▪The European Medicines Agency recommended granting a marketing authorisation in the European Union for Icotyde (icotrokinra) on July 24, 2026.
  • ▪Plaque psoriasis is a chronic inflammatory skin disease affecting 1% to 4% of adults and up to 1% of children worldwide.

Icotrokinra interleukin-23 receptor blockade

  • ▪The active substance in Icotyde, icotrokinra, works by blocking the receptor for interleukin-23, a protein involved in plaque psoriasis inflammation.
  • ▪By blocking the action of interleukin-23, icotrokinra reduces inflammation and symptoms associated with plaque psoriasis.

First oral IL-23 pathway medicine

  • ▪While authorised injectable medicines targeting interleukin-23 are available in the European Union, Icotyde offers an oral alternative.
  • ▪Icotyde will be the first authorised oral medicine targeting the interleukin-23 pathway in the European Union.

Phase 3 trial efficacy outcomes

  • ▪In three phase 3 trials, 50% to 57% of patients taking Icotyde achieved a 90% or more drop in symptom scores after 16 weeks, compared to 1% to 4% taking placebo.
  • ▪The European Medicines Agency evaluated data from four phase 3 trials involving 2,500 patients with moderate-to-severe plaque psoriasis.
  • ▪A fourth phase 3 study evaluated Icotyde in patients with psoriasis affecting difficult-to-treat areas including the scalp, genital region, hands, and feet.

Favourable safety profile data

  • ▪Icotyde demonstrated a favourable safety profile in clinical trials, with fungal infections reported as the most common side effect.
  • ▪Fungal infections occurred in 1.1% of patients treated with Icotyde in clinical trials.

EU regulatory approval pathway

  • ▪Following potential European Commission approval, decisions regarding Icotyde's pricing and reimbursement will be made by individual European Union Member States.
  • ▪The Committee for Medicinal Products for Human Use opinion on Icotyde will be sent to the European Commission for an EU-wide marketing authorisation decision.
  • ▪Janssen-Cilag International N.V. is the applicant for the marketing authorisation of Icotyde.

1 source

Ema
First oral medicine targeting interleukin-23 receptor recommended for plaque psoriasis | European Medicines Agency (EMA)
View source article

Featured stories

FDA Approves Johnson & Johnson's Icotyde for Moderate-to-Severe Plaque Psoriasis

Mar 25, 2026 · 1 source

Story comments

Loading comments…

Related entities

European Medicines Agency

Topics

Drug Approval and Clinical TrialsDrug Policy, Pricing & Approval

Featured stories

FDA Approves Johnson & Johnson's Icotyde for Moderate-to-Severe Plaque Psoriasis

Mar 25, 2026 · 1 source